UPDATE: Piper Sandler Double Downgrades Humacyte (HUMA) to Underweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Humacyte First Quarter 2022 Financial Results and Business Update
May 13, 2022 7:00 AM EDT-- Human Acellular Vessels (HAVs) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries --
-- Strengthened leadership team with appointment of Shamik Parikh M.D., as Chief Medical Officer --
 -- Multiple scientific meeting presentations and publications highlighting clinical and preclinical HAV data --
-- Conference call and live webcast at 8:00 a.m. ET today --
DURHAM, N.C., May 13, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform... More
